Vemurafenib: First-in- Class BRAF-Mutated Inhibitor for the Treatment ofUnresectable or Metastatic Melanoma

LINDSAY SHELLEDY; DANIELLE ROMAN

首页> 外文期刊>Journal of the advanced practitioner in oncology >Vemurafenib: First-in- Class BRAF-Mutated Inhibitor for the Treatment ofUnresectable or Metastatic Melanoma

【24h】

Vemurafenib: First-in- Class BRAF-Mutated Inhibitor for the Treatment ofUnresectable or Metastatic Melanoma

机译：Vemurafenib：BRAF突变的一流抑制剂，用于治疗无法切除或转移的黑色素瘤

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Skin cancer is the most com-mon cancer in the UnitedStates, with more than 3.5million people diagnosed ev-ery year (American Cancer Society,2013). Melanoma is a life-threaten-ing form of skin cancer that occursdue to genetic and environmentalfactors.

机译：皮肤癌是美国最常见的癌症，每年被确诊的人数超过350万人（美国癌症协会，2013年）。黑色素瘤是一种危及生命的皮肤癌，由于遗传和环境因素而发生。

著录项

来源
《Journal of the advanced practitioner in oncology》 |2015年第4期|共5页
作者
LINDSAY SHELLEDY; DANIELLE ROMAN;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Vemurafenib: First-in- Class BRAF-Mutated Inhibitor for the Treatment ofUnresectable or Metastatic Melanoma [J] . LINDSAY SHELLEDY, DANIELLE ROMAN Journal of the advanced practitioner in oncology . 2015,第4期

机译：Vemurafenib：BRAF突变的一流抑制剂，用于治疗无法切除或转移的黑色素瘤
2. Case History. Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma. [J] . IbrahimP.N., ZhangJ., ZhangC., Annual reports in medicinal chemistry. . 2013,第Null期

机译：病历。 Vemurafenib是一种有效的，选择性的突变BRAF抑制剂，用于治疗转移性黑色素瘤。
3. EFFECTIVENESS AND SAFETY OF BRAF INHIBITORS IN THE TREATMENT OF BRAF-MUTATED UNRESECTABLE OR METASTATIC MELANOMA: REAL WORLD DATA [J] . Garcia-Avello A., Vega-Coca M. D., Abdel-Kader-Martin L., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：BRAF抑制剂治疗BRAF突变的无法手术或转移性黑色素瘤的有效性和安全性：真实世界数据
4. Overcoming Acquired Resistance in BRAFV600 Melanoma Using a Combination of ABI-274 and Vemurafenib in a Predictive A375RF21Model [C] . Wei Li, Jin Wang, Jianjun Chen, Molecular Medicine TRI-CON. . 2014

机译：使用ABI-274和VemureaFenib的组合在预测A375RF21MODEL中克服BRAF V600黑素瘤的耐受性
5. Mouse oocyte maturation and embryo development after exposure to Vemurafenib (plx4032), an anti-melanoma B-RafV600E inhibitor. [D] . Liu, Bo. 2014

机译：暴露于抗黑素瘤B-RafV600E抑制剂Vemurafenib（plx4032）后，小鼠卵母细胞成熟和胚胎发育。
6. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma [O] . Lindsay Shelledy, Danielle Roman 2015

机译：Vemurafenib：一流的BRAF突变型抑制剂用于治疗不可切除或转移性黑色素瘤
7. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma [O] . Lindsay Shelledy PharmD, Danielle Roman PharmD BCOP 2015

机译：vemurafenib：阶级Braf-突变的抑制剂，用于治疗不可切种或转移性黑色素瘤

Vemurafenib: First-in- Class BRAF-Mutated Inhibitor for the Treatment ofUnresectable or Metastatic Melanoma

摘要

著录项

相似文献

相关主题

期刊订阅